Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderate to Severe Plaque-type Psoriasis
NCT02325219Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Started Dec 2014; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02325219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325219.